tradingkey.logo

Regeneron Pharmaceuticals Inc

REGN
753.570USD
+12.280+1.66%
Market hours ETQuotes delayed by 15 min
79.35BMarket Cap
17.38P/E TTM

Regeneron Pharmaceuticals Inc

753.570
+12.280+1.66%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Regeneron Pharmaceuticals Inc

Currency: USD Updated: 2025-12-12

Key Insights

Regeneron Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 11/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 780.40.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Regeneron Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
11 / 159
Overall Ranking
53 / 4592
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 30 analysts
Buy
Current Rating
780.402
Target Price
+10.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Regeneron Pharmaceuticals Inc Highlights

StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.67% year-on-year.
Fairly Valued
The company’s latest PE is 17.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.26M shares, decreasing 4.27% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 735.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-12

The current financial score of Regeneron Pharmaceuticals Inc is 9.33, ranking 8/159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.75B, representing a year-over-year increase of 0.90%, while its net profit experienced a year-over-year increase of 8.91%.

Score

Industry at a Glance

Previous score
9.33
Change
0

Financials

8.26

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.51

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

9.85

Regeneron Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-12-12

The current valuation score of Regeneron Pharmaceuticals Inc is 7.52, ranking 67/159 in the Pharmaceuticals industry. Its current P/E ratio is 17.10, which is 74.40% below the recent high of 29.82 and 32.36% above the recent low of 11.56.

Score

Industry at a Glance

Previous score
7.52
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 11/159
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-12

The current earnings forecast score of Regeneron Pharmaceuticals Inc is 7.87, ranking 90/159 in the Pharmaceuticals industry. The average price target for Regeneron Pharmaceuticals Inc is 767.00, with a high of 1057.00 and a low of 627.00.

Score

Industry at a Glance

Previous score
7.87
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 30 analysts
Buy
Current Rating
780.402
Target Price
+10.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
30
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-12

The current price momentum score of Regeneron Pharmaceuticals Inc is 7.52, ranking 71/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 792.86 and the support level at 687.83, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.98
Change
-1.46

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-11.856
Neutral
RSI(14)
58.829
Neutral
STOCH(KDJ)(9,3,3)
60.445
Buy
ATR(14)
21.168
High Vlolatility
CCI(14)
-5.874
Neutral
Williams %R
50.131
Neutral
TRIX(12,20)
0.404
Sell
StochRSI(14)
87.350
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
722.028
Buy
MA10
726.708
Buy
MA20
734.973
Buy
MA50
660.768
Buy
MA100
615.913
Buy
MA200
599.305
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-12

The current institutional shareholding score of Regeneron Pharmaceuticals Inc is 10.00, ranking 1/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 91.26%, representing a quarter-over-quarter decrease of 4.62%. The largest institutional shareholder is The Vanguard, holding a total of 9.00M shares, representing 8.71% of shares outstanding, with 1.20% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
9.37M
+0.16%
BlackRock Institutional Trust Company, N.A.
5.67M
-1.32%
State Street Investment Management (US)
4.83M
+0.88%
3.83M
+64.64%
JP Morgan Asset Management
2.82M
-30.95%
Geode Capital Management, L.L.C.
2.47M
-0.18%
Invesco Capital Management (QQQ Trust)
2.17M
-0.35%
Putnam Investment Management, L.L.C.
2.03M
+6.08%
Capital World Investors
1.97M
+1.41%
Loomis, Sayles & Company, L.P.
1.94M
+18.65%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-12

The current risk assessment score of Regeneron Pharmaceuticals Inc is 8.57, ranking 29/159 in the Pharmaceuticals industry. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
8.57
Change
0
Beta vs S&P 500 index
0.39
VaR
+2.64%
240-Day Maximum Drawdown
+35.14%
240-Day Volatility
+40.79%

Return

Best Daily Return
60 days
+11.82%
120 days
+11.82%
5 years
+18.85%
Worst Daily Return
60 days
-4.67%
120 days
-4.67%
5 years
-19.01%
Sharpe Ratio
60 days
+2.54
120 days
+2.39
5 years
+0.50

Risk Assessment

Maximum Drawdown
240 days
+35.14%
3 years
+59.80%
5 years
+59.80%
Return-to-Drawdown Ratio
240 days
+0.12
3 years
-0.01
5 years
+0.20
Skewness
240 days
-1.17
3 years
-1.24
5 years
-0.04

Volatility

Realised Volatility
240 days
+40.79%
5 years
+31.56%
Standardised True Range
240 days
+2.76%
5 years
+2.45%
Downside Risk-Adjusted Return
120 days
+443.06%
240 days
+443.06%
Maximum Daily Upside Volatility
60 days
+35.76%
Maximum Daily Downside Volatility
60 days
+24.65%

Liquidity

Average Turnover Rate
60 days
+0.97%
120 days
+1.08%
5 years
--
Turnover Deviation
20 days
+38.23%
60 days
+41.71%
120 days
+58.49%

Peer Comparison

Pharmaceuticals
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
REGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
JAZZ
8.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
United Therapeutics Corp
UTHR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Regeneron Pharmaceuticals Inc?

The TradingKey Stock Score provides a comprehensive assessment of Regeneron Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Regeneron Pharmaceuticals Inc’s performance and outlook.

How do we generate the financial health score of Regeneron Pharmaceuticals Inc?

To generate the financial health score of Regeneron Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Regeneron Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Regeneron Pharmaceuticals Inc.

How do we generate the company valuation score of Regeneron Pharmaceuticals Inc?

To generate the company valuation score of Regeneron Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Regeneron Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Regeneron Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Regeneron Pharmaceuticals Inc.

How do we generate the earnings forecast score of Regeneron Pharmaceuticals Inc?

To calculate the earnings forecast score of Regeneron Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Regeneron Pharmaceuticals Inc’s future.

How do we generate the price momentum score of Regeneron Pharmaceuticals Inc?

When generating the price momentum score for Regeneron Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Regeneron Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Regeneron Pharmaceuticals Inc.

How do we generate the institutional confidence score of Regeneron Pharmaceuticals Inc?

To generate the institutional confidence score of Regeneron Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Regeneron Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Regeneron Pharmaceuticals Inc.

How do we generate the risk management score of Regeneron Pharmaceuticals Inc?

To assess the risk management score of Regeneron Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Regeneron Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Regeneron Pharmaceuticals Inc.
KeyAI